Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 554

1.
2.
4.

Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.

Mora S, Rifai N, Buring JE, Ridker PM.

Circulation. 2008 Sep 2;118(10):993-1001. doi: 10.1161/CIRCULATIONAHA.108.777334. Epub 2008 Aug 18.

6.

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R; Heart Protection Study Collaborative Group.

Circulation. 2012 May 22;125(20):2469-78. doi: 10.1161/CIRCULATIONAHA.111.073684. Epub 2012 Apr 26.

7.

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS.

JAMA. 2007 Aug 15;298(7):776-85.

PMID:
17699011
8.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

9.

Lipid levels and the risk of ischemic stroke in women.

Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM.

Neurology. 2007 Feb 20;68(8):556-62.

10.

Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.

Andersson C, Lyass A, Vasan RS, Massaro JM, D'Agostino RB Sr, Robins SJ.

Am Heart J. 2014 Dec;168(6):878-83.e1. doi: 10.1016/j.ahj.2014.08.007. Epub 2014 Sep 16.

PMID:
25458651
11.

Summaries for patients. Does low-density lipoprotein cholesterol influence the relationship between high-density lipoprotein cholesterol and cardiovascular risk in women?

[No authors listed]

Ann Intern Med. 2011 Dec 6;155(11):I56. doi: 10.7326/0003-4819-155-11-201112060-00003. No abstract available.

PMID:
22147728
12.

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM.

Circulation. 2015 Dec 8;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857. Epub 2015 Sep 25.

PMID:
26408274
13.

The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women.

Everett BM, Kurth T, Buring JE, Ridker PM.

J Am Coll Cardiol. 2006 Dec 5;48(11):2235-42. Epub 2006 Nov 13.

14.

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S.

J Am Coll Cardiol. 2012 Aug 7;60(6):508-16. doi: 10.1016/j.jacc.2012.03.060. Epub 2012 Jul 11.

15.

Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.

Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Watanabe K, Watanabe Y, Mishina H, Kugiyama K.

Atherosclerosis. 2011 Sep;218(1):163-7. doi: 10.1016/j.atherosclerosis.2011.04.040. Epub 2011 May 6.

PMID:
21605862
16.

The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography.

Song Y, Yang Y, Zhang J, Wang Y, He W, Zhang X, Zhu J, Lu Z.

Lipids Health Dis. 2015 Nov 18;14:150. doi: 10.1186/s12944-015-0155-6.

17.

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ.

JAMA. 2012 Mar 28;307(12):1302-9. doi: 10.1001/jama.2012.366. Erratum in: JAMA. 2012 May 9;307(18):1915. JAMA. 2012 Apr 25;307(16):1694.

PMID:
22453571
18.

Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population based cohort study.

Tohidi M, Hatami M, Hadaegh F, Safarkhani M, Harati H, Azizi F.

Lipids Health Dis. 2010 Jan 23;9:6. doi: 10.1186/1476-511X-9-6.

19.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

20.

Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.

Straczek C, Tafflet M, Barberger-Gateau P, Bertrand M, Dupuy AM, Ducimetière P, Empana JP.

Atherosclerosis. 2011 Feb;214(2):426-31. doi: 10.1016/j.atherosclerosis.2010.10.040. Epub 2010 Nov 3.

PMID:
21129746
Items per page

Supplemental Content

Write to the Help Desk